Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Substance P-Saporin
- Development stage
- Phase 1
- Lead developer
- Advanced Targeting Systems
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intrathecal
01
Overview
**Substance P-Saporin** is an investigational targeted neurotoxin conjugate developed for durable treatment of severe chronic pain, including opioid-refractory cancer pain. It consists of the endogenous tachykinin peptide substance P covalently linked through a disulfide-containing linkage to saporin, a type I ribosome-inactivating protein. Substance P directs the conjugate to neurokinin-1 receptor-expressing spinal neurons; receptor-mediated internalization enables saporin to enter the cytoplasm, inactivate ribosomes, stop protein synthesis, and permanently ablate these nociceptive relay neurons. It has been evaluated by intrathecal administration in a Phase 1 study in patients with terminal cancer and intractable pain. ([cancer.gov](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2014-00020))
- Other names
- SP-SAPsubstance P-saporin
02
Targets
TACR1 (Neurokinin‑1 Receptor)
Beyond the preview
Go deeper on Substance P-Saporin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Substance P-Saporin.